A Study Evaluating the Safety and Efficacy of Cura-100 in Subjects With Rheumatoid Arthritis and Osteoarthritis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00455208|
Recruitment Status : Unknown
Verified March 2007 by Cura Biotech LLC.
Recruitment status was: Not yet recruiting
First Posted : April 3, 2007
Last Update Posted : February 19, 2009
|Condition or disease||Intervention/treatment||Phase|
|Rheumatoid Arthritis Osteoarthritis||Drug: Cura-100||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Study Evaluating Cura-100 in Rheumatoid Arthritis and Osteoarthritis|
|Study Start Date :||May 2007|
|Estimated Study Completion Date :||December 2008|
- The primary outcome is remission of rheumatoid arthritis and osteoarthritis, which will be measured with ACR criteria.
- The secondary outcome is the reduction in signs and symptoms of rheumatoid arthritis and osteoarthritis for a continuous three or six month period, measured with ACR20 and the change from baseline in HAQ.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00455208
|United States, California|
|Cura Biotech LLC||Not yet recruiting|
|Sunnyvale, California, United States, 94087|
|Contact: Victor Zhang 408-774-1832 firstname.lastname@example.org|
|Principal Investigator: Lizhen Wang, MD|
|Study Director:||Victor Zhang||Cura Biotech LLC|